Figure 2
![Figure 2. Gene/phenotypic characterization within thrombocytosis cohorts. (A) Distribution of the 5 nsSNVs among the ET cohort by platelet JAK2V617F allelic burden. (B) ORs with confidence intervals (CIs) were calculated by thrombocytosis phenotype (ET, RT) using genotyped validation controls (N = 208); only BLVRBS111L remains a strong risk allele irrespective of thrombocytosis etiology (RT OR = 10.2; CI, 1.96-53.6; P = .005). (C-D) Hemoglobin and platelet counts plotted by JAK2V617F allelic burden (substratified by zygosity for BLVRB 462C→T [S111L] mutation) were fit by linear regressions.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/128/5/10.1182_blood-2016-02-696997/4/699f2.jpeg?Expires=1743073367&Signature=aDUs9hjmIo8sc6iQbQe-FWpjkiPKqLF~1TIk6wr5pIgsCePdQHpzijUmmKnvtNyAD43~Neq1ozuTfWpP3rvkQgFLtm3GabWotrhUY5MlTW5T9cASXWkUFlduhoJz54U8Dy5LEN2FUXdIo5~pJYIqe0-nfwWrZfbLcdNVFxE2y-JrOCzcqLHUbYZm-eoqTZYqQMZG-UZkkIxfdZFiEXUzbhnZcc5DYHNlCMM6TQ-Eo1UylzIcKJtdTBeMNE~7sMKBMV3qjiY-Zg2g76mgdEeGyHMsQHngOARfPHaAcVw9cmUUuGw7ASvkXBhrYz7pS~iLcg-bazV9hbQQ90FB8y8xIg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Gene/phenotypic characterization within thrombocytosis cohorts. (A) Distribution of the 5 nsSNVs among the ET cohort by platelet JAK2V617F allelic burden. (B) ORs with confidence intervals (CIs) were calculated by thrombocytosis phenotype (ET, RT) using genotyped validation controls (N = 208); only BLVRBS111L remains a strong risk allele irrespective of thrombocytosis etiology (RT OR = 10.2; CI, 1.96-53.6; P = .005). (C-D) Hemoglobin and platelet counts plotted by JAK2V617F allelic burden (substratified by zygosity for BLVRB 462C→T [S111L] mutation) were fit by linear regressions.
